Jiangsu Hengrui Pharmaceuticals (600276.SH): The clinical trial application for Fruquichuzhu monoclonal antibody injection has been approved.

16:52 13/02/2025

Hengrui Medicine (600276.SS) issued an announcement that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received a...

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the approval notification from the National Medical Products Administration for the clinical trials of the injection of Fuzhao Chi Zhu monoclonal antibody. The company will soon start the clinical trials. Fuzhao Chi Zhu monoclonal antibody injection is a recombinant humanized monoclonal antibody that targets human IL-17A, developed by the company, intended for the treatment of autoimmune diseases related to the IL-17 pathway.

New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.